AstraZeneca’s head of research and development has said the UK drugmaker would consider not submitting its Covid-19 vaccine for approval in the US if it finds it is “banging its head against a brick wall indefinitely” with regulators.
Sir Mene Pangalos said AstraZeneca would instead focus its attention on selling the vaccine it developed with Oxford university in other countries, though it will continue to talk to the Food and Drug Administration, the US regulator.
AstraZeneca has still not submitted the vaccine for approval after months of talks. Pascal Soriot, chief executive, said last April that the drugmaker planned to file within weeks.
您已閱讀20%（651字），剩余80%（2549字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。